Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATAS SAD and MAD Study in Healthy Volunteers and Type 2 Diabetes
NCT07223333Phase 1Recruiting
- Sponsor
- AdipoPharma
- Start
- Jan 2026
- Primary completion
- May 2027
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PATAS in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AdipoPharma. Primary endpoints: Safety and Tolerability at 29 days, Oral Glucose Tolerance Test at Day 28 and 10 more. Started Jan 2026; status: recruiting.
02
Drugs
PATAS
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07223333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223333.